CD8A and neoplasm: We and others previously demonstrated that tumor-specific CD8 T cells have unique properties and that immunotherapy primarily affects tumor-reactive versus bystander CD8 T cells.16,21,22,59–61 Therefore, we analyzed mLama4 neoAg-specific CD8 T cells (Figure 3A).